Cargando…

P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms

BACKGROUND: High grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) with a Ki67 proliferation index > 20%, include well-differentiated tumours grade 3 (NET G3) and poorly differentiated (PD) neuroendocrine carcinomas (NEC). Abnormal p53-expression is a feature of PD tumours, while...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nielsen, Kirstine, Binderup, Tina, Langer, Seppo W., Kjaer, Andreas, Knigge, Pauline, Grøndahl, Veronica, Melchior, Linea, Federspiel, Birgitte, Knigge, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953213/ https://www.ncbi.nlm.nih.gov/pubmed/31924180 http://dx.doi.org/10.1186/s12885-019-6498-z

Ejemplares similares

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
por: Ilett, Emma Elizabeth, et al.
Publicado: (2015)

Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation
por: Binderup, Tina, et al.
Publicado: (2013)

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
por: Baekdal, Jonas, et al.
Publicado: (2020)

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells
por: Døssing, Kristina B. V., et al.
Publicado: (2018)

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
por: Olsen, Ingrid Holst, et al.
Publicado: (2014)

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
por: Olsen, Ingrid H., et al.
Publicado: (2012)

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
por: Ali, Abir Salwa, et al.
Publicado: (2017)

Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm
por: Wang, Yu-hong, et al.
Publicado: (2014)

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
por: Ali, Abir Salwa, et al.
Publicado: (2018)

Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1
por: Døssing, Kristina B. V., et al.
Publicado: (2014)

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019)

Initial Experience with (64)Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET
por: Loft, Mathias, et al.
Publicado: (2021)

Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors
por: Stensbøl, Anna Bryan, et al.
Publicado: (2021)

Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases
por: Langer, Seppo W., et al.
Publicado: (2015)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors
por: Kjaer, Andreas, et al.
Publicado: (2015)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms
por: Ramachandran, Anupama, et al.
Publicado: (2022)

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Moonjin, et al.
Publicado: (2016)

Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Tian, Tiantian, et al.
Publicado: (2016)

The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors – A Single-Center Experience
por: Tsai, Hui-Jen, et al.
Publicado: (2021)

Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
por: Kawasaki, Kenta, et al.
Publicado: (2018)

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot
por: Fernandez, Cornelius J, et al.
Publicado: (2021)

A convolutional neural network for total tumor segmentation in [(64)Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms
por: Carlsen, Esben Andreas, et al.
Publicado: (2022)

Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
por: Nölting, Svenja, et al.
Publicado: (2012)

Clinical Usefulness of Plasma Chromogranin A in Pancreatic Neuroendocrine Neoplasm
por: Paik, Woo Hyun, et al.
Publicado: (2013)

Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kikut, Justyna, et al.
Publicado: (2020)

Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms
por: Mahečić, Davorka Herman, et al.
Publicado: (2020)

Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland
por: Alwan, Heba, et al.
Publicado: (2020)

The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
por: Venizelos, Andreas, et al.
Publicado: (2021)

Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Takayanagi, Daisuke, et al.
Publicado: (2022)

New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
por: Yin, Feng, et al.
Publicado: (2022)

Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
por: Dai, Meng, et al.
Publicado: (2022)

Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Budek, Marlena, et al.
Publicado: (2022)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lggq89o5nhtjda153ckq945o41